EP1082130A1 - Use of cyclosporins in the treatment of inflammatory autoimmune diseases - Google Patents

Use of cyclosporins in the treatment of inflammatory autoimmune diseases

Info

Publication number
EP1082130A1
EP1082130A1 EP99926489A EP99926489A EP1082130A1 EP 1082130 A1 EP1082130 A1 EP 1082130A1 EP 99926489 A EP99926489 A EP 99926489A EP 99926489 A EP99926489 A EP 99926489A EP 1082130 A1 EP1082130 A1 EP 1082130A1
Authority
EP
European Patent Office
Prior art keywords
ciclosporin
meleu
hydroxy
cyclophilin
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99926489A
Other languages
German (de)
English (en)
French (fr)
Inventor
Peter Hiestand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH
Novartis AG
Original Assignee
Novartis Erfindungen Verwaltungs GmbH
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Erfindungen Verwaltungs GmbH, Novartis AG filed Critical Novartis Erfindungen Verwaltungs GmbH
Publication of EP1082130A1 publication Critical patent/EP1082130A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
EP99926489A 1998-06-02 1999-05-31 Use of cyclosporins in the treatment of inflammatory autoimmune diseases Withdrawn EP1082130A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9811854.0A GB9811854D0 (en) 1998-06-02 1998-06-02 Organic compounds
GB9811854 1998-06-02
PCT/EP1999/003770 WO1999062540A1 (en) 1998-06-02 1999-05-31 Use of cyclosporins in the treatment of inflammatory autoimmune diseases

Publications (1)

Publication Number Publication Date
EP1082130A1 true EP1082130A1 (en) 2001-03-14

Family

ID=10833083

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99926489A Withdrawn EP1082130A1 (en) 1998-06-02 1999-05-31 Use of cyclosporins in the treatment of inflammatory autoimmune diseases

Country Status (17)

Country Link
EP (1) EP1082130A1 (no)
JP (2) JP4523154B2 (no)
KR (1) KR20010043969A (no)
CN (1) CN1304315A (no)
AU (1) AU750422B2 (no)
BR (1) BR9910860A (no)
CA (1) CA2333315A1 (no)
GB (1) GB9811854D0 (no)
HU (1) HUP0102142A3 (no)
ID (1) ID27576A (no)
IL (1) IL139589A0 (no)
NO (1) NO20006113L (no)
PL (1) PL344451A1 (no)
SK (1) SK18142000A3 (no)
TW (2) TWI250021B (no)
WO (1) WO1999062540A1 (no)
ZA (1) ZA200006464B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2243314T3 (es) 1999-10-27 2005-12-01 Alexandra Lucas Composiciones para la prevencion y el tratamiento del rechazo de trasplantes.
AU9157901A (en) * 2000-09-29 2002-04-08 Z Robert Zhong Methods of treating inflammatory and immune reactions and compositions therefor
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
JP2007532507A (ja) * 2004-04-08 2007-11-15 ノバルティス アクチエンゲゼルシャフト 脳虚血ならびに脳および脊髄傷害の処置のためのサイクロスポリンの使用
MX2007000503A (es) 2004-07-14 2007-03-08 Novartis Ag Uso de una combinacion de ciclosporina e interferon pegilado para el tratamiento de hepatitis c(hcv).
EP1793844B1 (en) * 2004-10-01 2010-12-08 Debiopharm S.A. Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
CN101084005A (zh) * 2004-12-23 2007-12-05 诺瓦提斯公司 用于黄病毒科治疗的化合物
EP1830871A1 (en) * 2004-12-23 2007-09-12 Novartis AG Compositions for hcv treatment
EP1893211B1 (en) * 2005-06-17 2011-09-14 Novartis AG Use of sanglifehrin in hcv
JP2007112775A (ja) * 2005-10-24 2007-05-10 Hamamatsu Univ School Of Medicine サイトメガロウイルス感染の処置におけるシクロスポリン類の使用
WO2009148615A1 (en) * 2008-06-06 2009-12-10 Scynexis, Inc. Cyclosporin analogs and their use in the treatment of hcv infections
CA2724523A1 (en) * 2008-06-06 2010-01-07 Scynexis, Inc. Novel macrocyclic peptides
AU2009334790B2 (en) 2008-12-31 2016-09-08 Scynexis, Inc. Derivatives of cyclosporin A
CA2782898A1 (en) * 2009-12-09 2011-06-16 Scynexis, Inc. Novel cyclic peptides
EP2900684A2 (en) 2012-09-29 2015-08-05 Novartis AG Cyclic peptides and use as medicines
WO2014063147A1 (en) * 2012-10-19 2014-04-24 Scynexis, Inc. New antiviral macrocycles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0484281T4 (da) * 1990-11-02 2001-02-05 Novartis Ag Cyclosporiner
US6124453A (en) * 1995-07-04 2000-09-26 Novartis Ag Macrolides
AR006514A1 (es) * 1995-07-04 1999-09-08 Sandoz Ag Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende
CZ288631B6 (cs) * 1996-01-18 2001-08-15 Galena, A. S. Léčivé přípravky s obsahem cyklosporinu
CZ288739B6 (cs) * 1996-08-01 2001-08-15 Galena, A. S. Cyklosporin obsahující léčivé přípravky

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9962540A1 *

Also Published As

Publication number Publication date
TWI250022B (en) 2006-03-01
WO1999062540A1 (en) 1999-12-09
AU4372499A (en) 1999-12-20
JP2010059177A (ja) 2010-03-18
ID27576A (id) 2001-04-12
JP2002516873A (ja) 2002-06-11
SK18142000A3 (sk) 2001-06-11
JP4523154B2 (ja) 2010-08-11
TW200522975A (en) 2005-07-16
NO20006113D0 (no) 2000-12-01
TWI250021B (en) 2006-03-01
HUP0102142A3 (en) 2001-12-28
PL344451A1 (en) 2001-11-05
KR20010043969A (ko) 2001-05-25
NO20006113L (no) 2001-01-25
GB9811854D0 (en) 1998-07-29
AU750422B2 (en) 2002-07-18
ZA200006464B (en) 2002-03-11
CA2333315A1 (en) 1999-12-09
IL139589A0 (en) 2002-02-10
HUP0102142A2 (hu) 2001-11-28
BR9910860A (pt) 2001-03-06
CN1304315A (zh) 2001-07-18

Similar Documents

Publication Publication Date Title
AU750422B2 (en) Use of cyclosporins in the treatment of inflammatory autoimmune diseases
US6809077B2 (en) Cyclosporin analogs for the treatment of autoimmune diseases
AU2008203031B2 (en) Use of modified cyclosporins for the treatment of HCV disorders
US6979671B2 (en) Cyclosporins for the treatment of immune disorders
KR100248030B1 (ko) 시토킨 조절제 및 시토킨 농도 변화에 관련된 병변 및 질환에 있어서 그의 용도
US20070249527A1 (en) Cyclosporin Derivatives for the Treatment of Immune Disorders
US20030186855A1 (en) Cyclosporins for the treatment of immune disorders
US8450281B2 (en) Non-immunosuppressive cyclosporin for treatment of Ullrich congenital muscular dystrophy
EP0414632B1 (en) Cyclosporin derivatives
JP2002516873A5 (no)
CA2665415A1 (en) Use of modified cyclosporins
US20080194470A1 (en) Nim811 In Cerebral Ischemia and Brain and Spinal Cord Injury
WO1993017039A1 (en) Iso-cyclosporin salts
MXPA06011591A (en) Nim811 in cerebral ischemia and brain and spinal cord injury
NZ576523A (en) Use of modified cyclosporins

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001103

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: SI PAYMENT 20001103

17Q First examination report despatched

Effective date: 20010321

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.

Owner name: NOVARTIS AG

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 38/13 A, 7A 61P 37/06 B

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20021107